Olaparib monohydrate is a PARP inhibitor used to treat cancers with BRCA mutations, including ovarian, breast, pancreatic, and prostate cancers. It works by blocking DNA repair in cancer cells, leading to cell death. Used as both treatment and maintenance therapy after chemotherapy. It is grouped under the following drug class(es): Antineoplastic agents and PARP Inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Olaparib hydrate and Lynparza. Its PubChem CID is 168798820.
Olaparib monohydrate
| CAS No | 2093369-28-7 |
|---|---|
| Molecular Formula | C24H25FN4O4 |
| Molecular Weight | 452.5 g/mol |
| Synonyms | 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Olaparib monohydrate is a PARP inhibitor used to treat cancers with BRCA mutations, including ovarian, breast, pancreatic, and prostate cancers. It works by blocking DNA repair in cancer cells, leading to cell death.
The listed CAS number is 2093369-28-7.
The listed molecular formula is C24H25FN4O4.
The listed molecular weight is 452.5 g/mol.
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one;hydrate.
The source lists Olaparib hydrate and Lynparza.